In Korea, only 11.7% of patients with ischemic stroke have received thrombolytic therapy with tPA [4]; therefore, the translation of novel molecules with brain-protective effects into therapies with high efficiency and a wide therapeutic time window is vital [5,6,7,8,9]. This evidence concerns the gene PLAT and ischemic stroke.